as well as for myeloperoxidase and esterase.
The patient was treated with cytosine g/m' every I 2 hours for six consecutive days) and mg/m' daily for three days). This therapy was tolerated fourth complete remission was attained.
At the time of the patient has stayed in unmaintained remission for six is currently leading a normal life.
The patient was advised of the BMT and dures and the attendant risks in accordance with guidelines, and gave informed consent. BFU-E'#{176}and CFU-C' were assayed as described with minor modifications. BFU-E were plucked for cytogenetic analysis as early as day 1 1 and CFU-C on day 7, in order to make sure that a significant number of proliferating cells was present. 
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